By designing DCs to present tumor antigens on syngeneic MHC class I and provide allo-CD4+ T cell help through mismatched MHC class II, we achieved potent coordination between CTLs and helper T cells to reinforce antitumor immunity. Here, HLA-C is linked to neoplasm.